Free tool
FAERS Monitor: Xeljanz
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 213082 or its brand name (Xeljanz, Tofacitinib Citrate). Reports on generic versions are filed under their own applications.
Reports
107,010
Serious
65,558
61% of reports
Hospitalization
19,573
Death reported
8,054
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective31,730
- pain17,197
- rheumatoid arthritis17,065
- arthralgia14,265
- off label use13,206
- condition aggravated13,157
- fatigue13,129
- joint swelling12,494
- drug intolerance11,519
- rash10,773
- headache9,470
- abdominal discomfort9,187
- synovitis9,149
- arthropathy8,624
- alopecia8,446
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2008 | 1 |
| 2009 | 1 |
| 2011 | 1 |
| 2012 | 28 |
| 2013 | 1,742 |
| 2014 | 2,728 |
| 2015 | 4,589 |
| 2016 | 7,933 |
| 2017 | 8,366 |
| 2018 | 10,282 |
| 2019 | 12,768 |
| 2020 | 15,351 |
| 2021 | 10,605 |
| 2022 | 12,353 |
| 2023 | 7,021 |
| 2024 | 6,600 |
| 2025 | 4,953 |
| 2026 | 1,688 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,947,149 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| synovitisSignal | 9,149 | 201.2 | 195.5 | 899,430 |
| arthropathySignal | 8,624 | 35.9 | 35.1 | 247,886 |
| rheumatoid arthritisSignal | 17,065 | 34.6 | 34.1 | 475,559 |
| drug intoleranceSignal | 11,519 | 26.5 | 26.0 | 249,813 |
| joint swellingSignal | 12,494 | 22.6 | 22.2 | 232,290 |
| abdominal discomfortSignal | 9,187 | 11.3 | 11.1 | 82,435 |
| condition aggravatedSignal | 13,157 | 8.8 | 8.7 | 88,864 |
| alopeciaSignal | 8,446 | 8.8 | 8.6 | 56,305 |
| arthralgiaSignal | 14,265 | 6.9 | 6.8 | 71,545 |
| painSignal | 17,197 | 5.6 | 5.6 | 65,594 |
| rashSignal | 10,773 | 5.0 | 4.9 | 33,870 |
| drug ineffectiveSignal | 31,730 | 4.8 | 4.8 | 100,144 |
| fatigueSignal | 13,129 | 3.4 | 3.3 | 22,145 |
| headacheSignal | 9,470 | 3.0 | 2.9 | 12,808 |
| off label useSignal | 13,206 | 3.0 | 2.9 | 18,026 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.